Lead Product(s): GJB2 Gene Therapy
Therapeutic Area: Otolaryngology (Ear, Nose, Throat)
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2020
Otonomy is currently evaluating a series of compounds being tested for otoprotection against loss of hearing caused by cisplatin (CIHL).